TBC1 domain family member 10BGenealiases: EPI64B · FP2461
Q-omics provides the consensus-scored TBC1D10B profile across patient tissues and cancer cell-line models. TBC1D10B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TBC1D10B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TBC1D10B RNA expression shows 19,452 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where TBC1D10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D10B survival associations across molecular data types. TBC1D10B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D10B RNA expression–survival associations across cancer types. High TBC1D10B expression shows unfavorable associations in LIHC, ACC, COAD and MESO, but favorable associations in KIRC and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TBC1D10B RNA expression.
This table summarizes TBC1D10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D10B shows higher tumor expression in HNSC, KIRP, KIRC, COAD, BLCA and LIHC. The HNSC box plot shows higher TBC1D10B RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with TBC1D10B in patient tissues and cancer cell lines. In patient samples, TBC1D10B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
